Use of warfarin in long-term care: a systematic review

Background: The use of warfarin in older patients requires special consideration because of concerns with comorbidities, interacting medications, and the risk of bleeding. Several studies have suggested that warfarin may be underused or inconsistently prescribed in long-term care (LTC); no published systematic review has evaluated warfarin use for stroke prevention in this setting.

This review was conducted to summarize the body of published original research regarding the use of warfarin in the LTC population.

Results: Twenty-two studies met the inclusion criteria for this review. Atrial fibrillation (AF) was the most common indication for warfarin use in LTC and use of warfarin for stroke survivors was common.

Rates of warfarin use in AF were low in 5 studies, ranging from 17% to 57%. These usage rates were low even among residents with high stroke risk and low bleeding risk.

Scored bleeding risk had no apparent association with warfarin use in AF. In physician surveys, factors associated with not prescribing warfarin included risk of falls, dementia, short life expectancy, and history of bleeding. International normalized ratio was in the target range approximately half of the time.

The combined overall rate of warfarin-related adverse events and potential events was 25.5 per 100 resident months on warfarin therapy.

Download whole document
Use of warfarin in long-term care
Documento Adobe Acrobat 541.6 KB